金河生物(002688.SZ)：预计2025年净利润同比下降58.08%-70.06%

Core Viewpoint - The company Jinhe Biology (002688.SZ) expects a significant decline in net profit for 2025, projecting a range of 30 million to 42 million yuan, which represents a decrease of 70.06% to 58.08% compared to the previous year [1] Financial Performance - The net profit attributable to shareholders is forecasted to be between 30 million and 42 million yuan, indicating a substantial decline [1] - The net profit after deducting non-recurring gains and losses is expected to be between 9.5 million and 13.5 million yuan, reflecting a decrease of 88.66% to 83.89% year-on-year [1] Business Segments - The veterinary chemical drug segment continues to perform well, with sales of the main product, chlortetracycline, increasing in both domestic and international markets, particularly in overseas sales [1] - The company's sixth-phase project has commenced production, leading to increased output that meets domestic and international market demand, thereby generating additional profits [1] - The environmental services segment has also seen a rise in operating income, contributing significantly to overall performance [1]